Document is current
Any future updates will be listed below
-
Authors
Hisey, Erin E. http://orcid.org/0000-0001-6517-2522
Fritsch, Emma L. http://orcid.org/0000-0002-4083-6772
Newman, Emily L. http://orcid.org/0000-0003-0978-1600
Ressler, Kerry J. http://orcid.org/0000-0002-5158-1103
Kangas, Brian D. http://orcid.org/0000-0002-4597-9801
Carlezon, William A. Jr. http://orcid.org/0000-0002-4162-3947
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (T32MH125786, P50MH115874, P50MH115874, R01MH063266)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA047575)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 28 March 2023
Revised: 8 May 2023
Accepted: 10 May 2023
First Online: 31 May 2023
Competing interests
: WAC and KJR are members of the NPP editorial board. WAC is a consultant for Psy Therapeutics and has sponsored research agreements with Cerevel Therapeutics and Delix Therapeutics. BDK has sponsored research agreements with Compass Pathways, Delix Therapeutics, Engrail Therapeutics, Neurocrine Biosciences, Psy Therapeutics, and Takeda. KJR has performed scientific consultation for Bioxcel, Bionomics, Acer, Takeda, and Jazz Pharma; serves on Scientific Advisory Boards for Sage and the Brain Research Foundation, and he has received sponsored research support from Takeda, Brainsway, and Alto Neuroscience. EH, EF, and ELN report no competing interests.
